Full Press Release Details
SITC 37 th Annual Meeting (https:// jitc.bmj.com /content/10/Suppl_2/A858) Ectopic expression of EPN1 may also enable efficacious targeting through use of T cell engagers Correlations lead to identification of actionable public targets Immunome Discovery Engine 2.0: Context Dependent Drug Discovery Beyond Memory B - cells: What Other Immune Components Play a Role in Response? 28 Copyright 2023 Immunome, Inc.
Mora et al, 2016. J. Cell Mol. Cell Biol. 2016;8 (5):426 2. Wei et al. J. Cell Mol. Med. 2016;00 :1 M e d i a 0 h 4 h 1 6 h 0 h 4 h 1 6 h 0 h 4 h 1 6 h 0 h 4 h 1 6 h 0 h 4 h 1 6 h 0 h 4 h 1 6 h 0 1000 2000 3000 4000 5000 I L - 3 8 ( p g / m L ) 786O HuH7 MDA MB231 SKMEL28 SKOV3A549 Lung Renal Liver Breast Skin Ovarian Takeda et al. PLoS One (2017) 23 IMM - ONC - 01 Program Summary Copyright 2023 Immunome, Inc.
Tumor Cells Can Secrete IL - 38 Upon Apoptosis Induction IL - 38 Levels Correlate with PD - L1 Expression IL - 38 secretion associated with apoptotic cell death 1 Acts during tissue damage to limit unwanted immune activation 2 Human tumor cells from multiple tumor types secrete IL - 38 during apoptosis in vitro PD - L1 positive cases exhibited higher levels of IL - 38 expression than PD - L1 negative cases (P < 0.0001) 1.
Immunome Internal Data IL - 38 Expression Confirmed in Multiple Tumors of High Unmet Medical Need 1 IL - 38 Overexpression Inhibits Infiltration of T cells into Tumors In Vivo High IL - 38 Expression is Associated with Reduced Immune Cell Infiltration* IL - 38 high tumor samples correlate with reduced infiltration of multiple immune subsets, especially in lung, head & neck, and gastroesophageal cancers IL - 38 Expression is Associated with Reduced Immune Cell Infiltration 20 Copyright 2023 Immunome, Inc.
Sinus Stage III. T3N0M0 SCC of Tongue root Stage II. T2N0M0 ACC of Parotid Stage II. T2N0M0 Isotype Control Anti IL - 38 (Immunome Clone) Weak Moderate Strong Head & Neck Lung, Squamous Esophagus Cervix Skin Lung, Adeno 23% 53% 41% 48% 25% 14% 30% 9% Bladder Prostate log2TPM log2TPM 1. Source: Tempus Real - World Data 2. Cancer Genome Atlas (TCGA) data from Firehouse Legacy dataset 3.
(nM) % C y t o t o x i c i t y Antibody B -Vc-MMAF anti-RSV-Vc-MMAF Unconj. Vc-MMAF Cetuximab-Vc-MMAF Trastuzumab (Her2) Free MMAF Anti - RSV - VC - MMAF Antibody B - VC - MMAF Cetuximab (EGFR) - VC - MMAF Trastuzumab (Her2) - VC - MMAF Internalization Patient - derived Ab Suitable for ADC Format Neg Cntrl Antibody B IMM - ONC - 01 Anti IL - 38 Antibody Copyright 2023 Immunome, Inc.
Our Discovery Engine identifies ectopic targets and antibodies simultaneously Represent a novel class of targets potentially suitable for development of next generation ADC (antibody - drug conjugate) and TCE (T cell engager) therapeutics High Throughput Functional Characterization: Proof of Concept Example of an Ectopically Expressed Target as an ADC 15 Copyright 2023 Immunome, Inc.
DoD JPEO - CBRND in collaboration with DHA Various Malignancies Oncology, Hematological Auto - Immune Disorders Immunology Immune Disorders Neuroinflammation Neurology Up to 10 novel antibody - target pairs in 3 tumor types Potential Future Therapeutic Areas Immunome Pipeline Targets Identified from Authentic Human Immune Response 10 Copyright 2023 Immunome, Inc.
Food and Drug Administration or other governmental authority. No representation is made as to the safety or effectiveness of these current or potential future product candidates for the use for which such product candidates are being studied. This presentation does not constitute an offering of securities of any kind. Immunome "At a Glance" Disruptive Technology Leveraging Human Immune Response 3 Copyright 2023 Immunome, Inc.
These statements and predictions involve risks and uncertainties based on various factors and evolution over time and, therefore, actual dates for these milestones may differ. In this presentation and oral commentary, we may discuss our current and potential future product candidates that have not yet undergone clinical trials or been approved for marketing by the U.S.
While we believe that information provides a reasonable basis for these statements, it may be limited or incomplete and we may have not independently verified it. Our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review or verification of, all relevant information. We make statements and predictions about future dates for achievement of milestones related to our platform and our programs in this presentation.
Statements that "we believe" and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based on information available to us as of the date of this presentation, including independent market research, industry publications and surveys, governmental agency publications and other publicly available information.
All statements contained in this presentation are made as of the date specified on the cover, and we undertake no duty to publicly update or revise any such statements, whether as a result of new information, future events or otherwise, except as may be required under applicable law. This presentation may contain product names, trade names, trademarks and service marks of Immunome and of other organizations, which are the properties of their respective owners.
Factors that could cause actual results to differ include, but are not limited to, the following: our ability to execute on our strategy, including with respect to R&D efforts, IND submissions and other regulatory filings, timing of these filings and the timing and nature of governmental authority feedback regarding the same, initiation and completion of any clinical studies, confirmatory testing and other anticipated milestones as and when anticipated; the fact that research and development data are subject to differing interpretations and assessments, including during the peer review/publication process in the scientific community and by regulatory authorities; whether our data will be published in a scientific journal and, if so, when and with what modifications; the effectiveness of our product candidates, including the possibility that further preclinical data and any clinical trial data may be inconsistent with earlier - published data and/or data used for advancing the product candidates; the fact that changes in the profile of the diseases that our programs target could emerge that could impact our ability to address those changes; our ability to fund operations; our reliance on vendors; our ability to execute on our plans for collaborations and partnerships; the competitive landscape; the impact of the COVID - 19 pandemic on our business, operations, strategy, goals and anticipated milestones; and the additional risks and uncertainties set forth more fully under the caption "Risk Factors" in Immunome's Annual Report on Form 10 - K filed with the United States Securities and Exchange Commission (SEC) on March 28, 2022, and elsewhere in Immunome's Quarterly Reports on form 10 - Q and other filings and reports with the SEC.
Forward - looking statements may be identified by the words "anticipate," believe," "estimate," "expect," "intend," "plan," "project," "suggest," "may," "will," "could," "should," "seek," "potential" and similar expressions. Forward - looking statements are based on our current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict.